[Biologic response modifiers for juvenile idiopathic arthritis]

Area of Science:

• Pediatrics
• Rheumatology
• Immunology

Background:

• Juvenile idiopathic arthritis (JIA) comprises distinct subtypes, systemic JIA and arthritic JIA, with differing clinical presentations, disease courses, and responses to therapy.
• Effective management necessitates tailored diagnostic and therapeutic strategies for each JIA subtype.

Purpose of the Study:

• To delineate the key differences between systemic JIA and arthritic JIA.
• To outline the diagnostic processes and treatment strategies appropriate for each subtype.

Main Methods:

• Diagnosis of arthritic JIA involves physical examination, blood tests, X-rays, and MRI.
• Diagnosis of systemic JIA relies on recognizing characteristic clinical features (fever, rash, arthritis) and excluding other conditions.
• Treatment evaluation of novel agents for systemic JIA.

Main Results:

• Arthritic JIA treatment primarily uses low-dose methotrexate, with biologics like etanercept and infliximab for non-responders.
• Systemic JIA management traditionally relies on corticosteroids, with emerging evidence for IL-1Ra and tocilizumab (anti-IL-6 receptor antibody).

Conclusions:

• Distinct approaches are crucial for diagnosing and treating systemic JIA and arthritic JIA.
• While methotrexate is a primary treatment for arthritic JIA, systemic JIA shows promise with IL-1Ra and tocilizumab, offering new therapeutic avenues.